User profiles for "author:B Graham"
Barney S. GrahamMorehouse School of Medicine Verified email at msm.edu Cited by 93041 |
Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement
BL Graham, I Steenbruggen, MR Miller… - American journal of …, 2019 - atsjournals.org
Background: Spirometry is the most common pulmonary function test. It is widely used in the
assessment of lung function to provide objective information used in the diagnosis of lung …
assessment of lung function to provide objective information used in the diagnosis of lung …
[HTML][HTML] Animal models for COVID-19
C Muñoz-Fontela, WE Dowling, SGP Funnell, PS Gsell… - Nature, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of
coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the …
coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the …
Nanomaterials: applications in cancer imaging and therapy
JA Barreto, W O'Malley, M Kubeil, B Graham… - Advanced …, 2011 - Wiley Online Library
The application of nanomaterials (NMs) in biomedicine is increasing rapidly and offers
excellent prospects for the development of new non‐invasive strategies for the diagnosis …
excellent prospects for the development of new non‐invasive strategies for the diagnosis …
[HTML][HTML] Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
LR Baden, HM El Sahly, B Essink… - New England journal …, 2021 - Mass Medical Soc
Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
A Pegu, SE O'Connell, SD Schmidt, S O'Dell… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …
vaccine-induced protective immune responses, particularly as antibody titers wane over …
[HTML][HTML] Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7
The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …
[HTML][HTML] SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
KS Corbett, DK Edwards, SR Leist, OM Abiona… - Nature, 2020 - nature.com
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has
been declared a public health emergency of international concern. The CoV spike (S) …
been declared a public health emergency of international concern. The CoV spike (S) …
[HTML][HTML] An mRNA vaccine against SARS-CoV-2—preliminary report
LA Jackson, EJ Anderson, NG Rouphael… - New England journal …, 2020 - Mass Medical Soc
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate …
in late 2019 and spread globally, prompting an international effort to accelerate …
[HTML][HTML] Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
HM El Sahly, LR Baden, B Essink… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …